Total glucosides of paeony improve complete freund's adjuvant-induced rheumatoid arthritis in rats by inhibiting toll-like receptor 2-mediated tumor necrosis factor receptor-associated factor 6/ nuclear factor-kappa B pathway activation.
Identifieur interne : 000244 ( Main/Exploration ); précédent : 000243; suivant : 000245Total glucosides of paeony improve complete freund's adjuvant-induced rheumatoid arthritis in rats by inhibiting toll-like receptor 2-mediated tumor necrosis factor receptor-associated factor 6/ nuclear factor-kappa B pathway activation.
Auteurs : Huan Chen [République populaire de Chine] ; Yueqiang Wen [République populaire de Chine] ; Ting Pan [République populaire de Chine] ; Shijun Xu [République populaire de Chine]Source :
- Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan [ 2589-451X ] ; 2019.
Descripteurs français
- KwdFr :
- Adjuvant Freund (effets indésirables), Animaux (MeSH), Anti-inflammatoires (administration et posologie), Facteur de nécrose tumorale alpha (génétique), Facteur de nécrose tumorale alpha (immunologie), Facteur de transcription NF-kappa B (génétique), Facteur de transcription NF-kappa B (immunologie), Facteur-6 associé aux récepteurs de TNF (génétique), Facteur-6 associé aux récepteurs de TNF (immunologie), Glucosides (administration et posologie), Humains (MeSH), Mâle (MeSH), Médicaments issus de plantes chinoises (administration et posologie), Paeonia (composition chimique), Polyarthrite rhumatoïde (génétique), Polyarthrite rhumatoïde (immunologie), Polyarthrite rhumatoïde (traitement médicamenteux), Polyarthrite rhumatoïde (étiologie), Rat Sprague-Dawley (MeSH), Rats (MeSH), Récepteur de type Toll-2 (génétique), Récepteur de type Toll-2 (immunologie).
- MESH :
- administration et posologie : Anti-inflammatoires, Glucosides, Médicaments issus de plantes chinoises.
- composition chimique : Paeonia.
- effets indésirables : Adjuvant Freund.
- génétique : Facteur de nécrose tumorale alpha, Facteur de transcription NF-kappa B, Facteur-6 associé aux récepteurs de TNF, Polyarthrite rhumatoïde, Récepteur de type Toll-2.
- immunologie : Facteur de nécrose tumorale alpha, Facteur de transcription NF-kappa B, Facteur-6 associé aux récepteurs de TNF, Polyarthrite rhumatoïde, Récepteur de type Toll-2.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- étiologie : Polyarthrite rhumatoïde.
- Animaux, Humains, Mâle, Rat Sprague-Dawley, Rats.
English descriptors
- KwdEn :
- Animals (MeSH), Anti-Inflammatory Agents (administration & dosage), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (etiology), Arthritis, Rheumatoid (genetics), Arthritis, Rheumatoid (immunology), Drugs, Chinese Herbal (administration & dosage), Freund's Adjuvant (adverse effects), Glucosides (administration & dosage), Humans (MeSH), Male (MeSH), NF-kappa B (genetics), NF-kappa B (immunology), Paeonia (chemistry), Rats (MeSH), Rats, Sprague-Dawley (MeSH), TNF Receptor-Associated Factor 6 (genetics), TNF Receptor-Associated Factor 6 (immunology), Toll-Like Receptor 2 (genetics), Toll-Like Receptor 2 (immunology), Tumor Necrosis Factor-alpha (genetics), Tumor Necrosis Factor-alpha (immunology).
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Drugs, Chinese Herbal, Glucosides.
- chemical , adverse effects : Freund's Adjuvant.
- chemistry : Paeonia.
- drug therapy : Arthritis, Rheumatoid.
- etiology : Arthritis, Rheumatoid.
- genetics : Arthritis, Rheumatoid, NF-kappa B, TNF Receptor-Associated Factor 6, Toll-Like Receptor 2, Tumor Necrosis Factor-alpha.
- immunology : Arthritis, Rheumatoid, NF-kappa B, TNF Receptor-Associated Factor 6, Toll-Like Receptor 2, Tumor Necrosis Factor-alpha.
- Animals, Humans, Male, Rats, Rats, Sprague-Dawley.
Abstract
OBJECTIVE
To investigate the mechanism underlying anti-inflammatory and immunoregulatory effect of total glucosides of paeony (TGP) based on toll-like receptor 2 (TLR2) mediated tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6)/nuclear factor-kappa B (NF-κB) pathway activation in rats with rheumatoid arthritis.
METHODS
Adjuvant arthritis (AA) model was developed by complete freund's adjuvant (CFA) immunization. TGP (100, 50, 25 mg/kg) and celecoxib (2.8 mg/kg) were administered by intragastric administration for 21 d. Right hind paw swelling was assessed every 2 d. After 21 d, synovial changes of the ankle were detected by histopathology. CD4+ and CD8+ T cell amounts in peripheral blood were measured by flow-cytometrically. Gene and protein levels of toll-like receptor (TLR)2, TRAF6, tumor necrosis factor ligand superfamily member 6 (FASLG) in the spleen were assessed by RT-qPCR and Western Bolt, respectively. Nuclear expression of NF-κB p65 was detected by NF-κB p65 Assay Kit.
RESULTS
Paw swelling and synovium lesions were obviously aggravated in AA rats. These symptoms were significantly relieved by TGP. The ratio of CD4+/CD8+ T cell was increased in AA rats, while TGP reduced this increased ratio. Gene and protein levels of splenic TLR2, TFAR6 and FASLG, and nuclear NF-κB p65 in AA rats were significantly increased, but overtly inhibited by TGP.
CONCLUSION
These findings suggest that TGP's anti-inflammatory effect onRA in rats with CFA may be related to the downregulation of TLR2/TRAF6/NF-κB pathway and the regulation of T cell subsets.
PubMed: 32186105
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Total glucosides of paeony improve complete freund's adjuvant-induced rheumatoid arthritis in rats by inhibiting toll-like receptor 2-mediated tumor necrosis factor receptor-associated factor 6/ nuclear factor-kappa B pathway activation.</title><author><name sortKey="Chen, Huan" sort="Chen, Huan" uniqKey="Chen H" first="Huan" last="Chen">Huan Chen</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author><author><name sortKey="Wen, Yueqiang" sort="Wen, Yueqiang" uniqKey="Wen Y" first="Yueqiang" last="Wen">Yueqiang Wen</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author><author><name sortKey="Pan, Ting" sort="Pan, Ting" uniqKey="Pan T" first="Ting" last="Pan">Ting Pan</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Shijun" sort="Xu, Shijun" uniqKey="Xu S" first="Shijun" last="Xu">Shijun Xu</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:32186105</idno><idno type="pmid">32186105</idno><idno type="wicri:Area/Main/Corpus">000186</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000186</idno><idno type="wicri:Area/Main/Curation">000186</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000186</idno><idno type="wicri:Area/Main/Exploration">000186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Total glucosides of paeony improve complete freund's adjuvant-induced rheumatoid arthritis in rats by inhibiting toll-like receptor 2-mediated tumor necrosis factor receptor-associated factor 6/ nuclear factor-kappa B pathway activation.</title><author><name sortKey="Chen, Huan" sort="Chen, Huan" uniqKey="Chen H" first="Huan" last="Chen">Huan Chen</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author><author><name sortKey="Wen, Yueqiang" sort="Wen, Yueqiang" uniqKey="Wen Y" first="Yueqiang" last="Wen">Yueqiang Wen</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author><author><name sortKey="Pan, Ting" sort="Pan, Ting" uniqKey="Pan T" first="Ting" last="Pan">Ting Pan</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Shijun" sort="Xu, Shijun" uniqKey="Xu S" first="Shijun" last="Xu">Shijun Xu</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Chengdu University of Traditional Chinese Medicine, Chengdu 610075</wicri:regionArea><wicri:noRegion>Chengdu 610075</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan</title><idno type="eISSN">2589-451X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Anti-Inflammatory Agents (administration & dosage)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthritis, Rheumatoid (etiology)</term><term>Arthritis, Rheumatoid (genetics)</term><term>Arthritis, Rheumatoid (immunology)</term><term>Drugs, Chinese Herbal (administration & dosage)</term><term>Freund's Adjuvant (adverse effects)</term><term>Glucosides (administration & dosage)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>NF-kappa B (genetics)</term><term>NF-kappa B (immunology)</term><term>Paeonia (chemistry)</term><term>Rats (MeSH)</term><term>Rats, Sprague-Dawley (MeSH)</term><term>TNF Receptor-Associated Factor 6 (genetics)</term><term>TNF Receptor-Associated Factor 6 (immunology)</term><term>Toll-Like Receptor 2 (genetics)</term><term>Toll-Like Receptor 2 (immunology)</term><term>Tumor Necrosis Factor-alpha (genetics)</term><term>Tumor Necrosis Factor-alpha (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvant Freund (effets indésirables)</term><term>Animaux (MeSH)</term><term>Anti-inflammatoires (administration et posologie)</term><term>Facteur de nécrose tumorale alpha (génétique)</term><term>Facteur de nécrose tumorale alpha (immunologie)</term><term>Facteur de transcription NF-kappa B (génétique)</term><term>Facteur de transcription NF-kappa B (immunologie)</term><term>Facteur-6 associé aux récepteurs de TNF (génétique)</term><term>Facteur-6 associé aux récepteurs de TNF (immunologie)</term><term>Glucosides (administration et posologie)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Médicaments issus de plantes chinoises (administration et posologie)</term><term>Paeonia (composition chimique)</term><term>Polyarthrite rhumatoïde (génétique)</term><term>Polyarthrite rhumatoïde (immunologie)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Polyarthrite rhumatoïde (étiologie)</term><term>Rat Sprague-Dawley (MeSH)</term><term>Rats (MeSH)</term><term>Récepteur de type Toll-2 (génétique)</term><term>Récepteur de type Toll-2 (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Drugs, Chinese Herbal</term><term>Glucosides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Freund's Adjuvant</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Glucosides</term><term>Médicaments issus de plantes chinoises</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Paeonia</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Paeonia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adjuvant Freund</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>NF-kappa B</term><term>TNF Receptor-Associated Factor 6</term><term>Toll-Like Receptor 2</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term><term>Facteur de transcription NF-kappa B</term><term>Facteur-6 associé aux récepteurs de TNF</term><term>Polyarthrite rhumatoïde</term><term>Récepteur de type Toll-2</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term><term>Facteur de transcription NF-kappa B</term><term>Facteur-6 associé aux récepteurs de TNF</term><term>Polyarthrite rhumatoïde</term><term>Récepteur de type Toll-2</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>NF-kappa B</term><term>TNF Receptor-Associated Factor 6</term><term>Toll-Like Receptor 2</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Mâle</term><term>Rat Sprague-Dawley</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To investigate the mechanism underlying anti-inflammatory and immunoregulatory effect of total glucosides of paeony (TGP) based on toll-like receptor 2 (TLR2) mediated tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6)/nuclear factor-kappa B (NF-κB) pathway activation in rats with rheumatoid arthritis.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Adjuvant arthritis (AA) model was developed by complete freund's adjuvant (CFA) immunization. TGP (100, 50, 25 mg/kg) and celecoxib (2.8 mg/kg) were administered by intragastric administration for 21 d. Right hind paw swelling was assessed every 2 d. After 21 d, synovial changes of the ankle were detected by histopathology. CD4+ and CD8+ T cell amounts in peripheral blood were measured by flow-cytometrically. Gene and protein levels of toll-like receptor (TLR)2, TRAF6, tumor necrosis factor ligand superfamily member 6 (FASLG) in the spleen were assessed by RT-qPCR and Western Bolt, respectively. Nuclear expression of NF-κB p65 was detected by NF-κB p65 Assay Kit.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Paw swelling and synovium lesions were obviously aggravated in AA rats. These symptoms were significantly relieved by TGP. The ratio of CD4+/CD8+ T cell was increased in AA rats, while TGP reduced this increased ratio. Gene and protein levels of splenic TLR2, TFAR6 and FASLG, and nuclear NF-κB p65 in AA rats were significantly increased, but overtly inhibited by TGP.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These findings suggest that TGP's anti-inflammatory effect onRA in rats with CFA may be related to the downregulation of TLR2/TRAF6/NF-κB pathway and the regulation of T cell subsets.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32186105</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2589-451X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>08</Month></PubDate></JournalIssue><Title>Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan</Title><ISOAbbreviation>J Tradit Chin Med</ISOAbbreviation></Journal><ArticleTitle>Total glucosides of paeony improve complete freund's adjuvant-induced rheumatoid arthritis in rats by inhibiting toll-like receptor 2-mediated tumor necrosis factor receptor-associated factor 6/ nuclear factor-kappa B pathway activation.</ArticleTitle><Pagination><MedlinePgn>566-574</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE">To investigate the mechanism underlying anti-inflammatory and immunoregulatory effect of total glucosides of paeony (TGP) based on toll-like receptor 2 (TLR2) mediated tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6)/nuclear factor-kappa B (NF-κB) pathway activation in rats with rheumatoid arthritis.</AbstractText><AbstractText Label="METHODS">Adjuvant arthritis (AA) model was developed by complete freund's adjuvant (CFA) immunization. TGP (100, 50, 25 mg/kg) and celecoxib (2.8 mg/kg) were administered by intragastric administration for 21 d. Right hind paw swelling was assessed every 2 d. After 21 d, synovial changes of the ankle were detected by histopathology. CD4+ and CD8+ T cell amounts in peripheral blood were measured by flow-cytometrically. Gene and protein levels of toll-like receptor (TLR)2, TRAF6, tumor necrosis factor ligand superfamily member 6 (FASLG) in the spleen were assessed by RT-qPCR and Western Bolt, respectively. Nuclear expression of NF-κB p65 was detected by NF-κB p65 Assay Kit.</AbstractText><AbstractText Label="RESULTS">Paw swelling and synovium lesions were obviously aggravated in AA rats. These symptoms were significantly relieved by TGP. The ratio of CD4+/CD8+ T cell was increased in AA rats, while TGP reduced this increased ratio. Gene and protein levels of splenic TLR2, TFAR6 and FASLG, and nuclear NF-κB p65 in AA rats were significantly increased, but overtly inhibited by TGP.</AbstractText><AbstractText Label="CONCLUSION">These findings suggest that TGP's anti-inflammatory effect onRA in rats with CFA may be related to the downregulation of TLR2/TRAF6/NF-κB pathway and the regulation of T cell subsets.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yueqiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shijun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Meterial Medica Integration and Transformation for Brain Disorders, CDUTCM, Chengdu 610075, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Tradit Chin Med</MedlineTA><NlmUniqueID>8211546</NlmUniqueID><ISSNLinking>0255-2922</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048029">TNF Receptor-Associated Factor 6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-81-2</RegistryNumber><NameOfSubstance UI="D005620">Freund's Adjuvant</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005620" MajorTopicYN="N">Freund's Adjuvant</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029596" MajorTopicYN="N">Paeonia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048029" MajorTopicYN="N">TNF Receptor-Associated Factor 6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Arthritis, experimental</Keyword><Keyword MajorTopicYN="Y">Arthritis, rheumatoid</Keyword><Keyword MajorTopicYN="Y">CD4-CD8 ratio</Keyword><Keyword MajorTopicYN="Y">Fas ligand protein</Keyword><Keyword MajorTopicYN="Y">TNF receptor-associated factor 6</Keyword><Keyword MajorTopicYN="Y">Toll-like receptor 2</Keyword><Keyword MajorTopicYN="Y">Total glucosides of paeony</Keyword><Keyword MajorTopicYN="Y">Transcription factor RelA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32186105</ArticleId><ArticleId IdType="pii">2944</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Chen, Huan" sort="Chen, Huan" uniqKey="Chen H" first="Huan" last="Chen">Huan Chen</name></noRegion><name sortKey="Chen, Huan" sort="Chen, Huan" uniqKey="Chen H" first="Huan" last="Chen">Huan Chen</name><name sortKey="Pan, Ting" sort="Pan, Ting" uniqKey="Pan T" first="Ting" last="Pan">Ting Pan</name><name sortKey="Pan, Ting" sort="Pan, Ting" uniqKey="Pan T" first="Ting" last="Pan">Ting Pan</name><name sortKey="Wen, Yueqiang" sort="Wen, Yueqiang" uniqKey="Wen Y" first="Yueqiang" last="Wen">Yueqiang Wen</name><name sortKey="Wen, Yueqiang" sort="Wen, Yueqiang" uniqKey="Wen Y" first="Yueqiang" last="Wen">Yueqiang Wen</name><name sortKey="Xu, Shijun" sort="Xu, Shijun" uniqKey="Xu S" first="Shijun" last="Xu">Shijun Xu</name><name sortKey="Xu, Shijun" sort="Xu, Shijun" uniqKey="Xu S" first="Shijun" last="Xu">Shijun Xu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000244 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000244 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32186105
|texte= Total glucosides of paeony improve complete freund's adjuvant-induced rheumatoid arthritis in rats by inhibiting toll-like receptor 2-mediated tumor necrosis factor receptor-associated factor 6/ nuclear factor-kappa B pathway activation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32186105" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |